Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer.
M. Basik
No relevant relationships to disclose
D. Keilty
No relevant relationships to disclose
O. Aleynikova
No relevant relationships to disclose
D. Tu
No relevant relationships to disclose
X. Li
No relevant relationships to disclose
L. E. Shepherd
No relevant relationships to disclose
V. Bramwell
No relevant relationships to disclose